Psyched Wellness To Conduct Stability Tests On Proprietary Mushroom Extract
Psyched Wellness (CSE: PSYC) is progressing with the development of its flagship product, an extract of Amanita Muscaria. The company
Read more
Psyched Wellness
Psyched Wellness Completes 14 Day Oral Toxicity Preclinical Study For Proprietary Extract
Psyched Wellness (CSE: PSYC) this morning announced the results of its initial 14-day oral toxicity preclinical study. The study was
Read more
Psyched Wellness Commences 90-Day Toxicity Study Of AME-1
Psyched Wellness (CSE: PSYC) continues to progress on its preclinical studies for its novel mushroom extract formulation. The company this
Read more
Psychedelics: Sector Tailwinds To Come – The Daily Dive feat Psyched Wellness CEO Jeff Stevens
Starting off the short Canadian trading week this week on the Daily Dive is that of Jeff Stevens, CEO of
Read more
Psyched Wellness Signs Two Year Supply Agreement For Amanita Muscaria
Psyched Wellness (CSE: PSYC) this morning had a brief announcement. Within, the company revealed that it has entered into a
Read more
Psyched Wellness Launches Study On Mushroom Extract Focused On Gut Health
Psyched Wellness (CSE: PSYC) this morning issued a very brief press release related to ongoing studies. The firm has initiated
Read more
Psyched Wellness Files Patent Application For Proprietary AME-1 Extraction Process
Psyched Wellness (CSE: PSYC) has begun the process of protecting its intellectual property. The firm this morning announced that it
Read more
David Nutt: Amanita Muscaria Due For More Research – The Daily Dive
Today on the Daily Dive, our host Cassandra Leah sits down with Dr David Nutt, a highly experienced neuropsychopharmacologist, the
Read more
Psyched Wellness: Canaccord Pens “Future In Fungi Report”
Yesterday morning, Canaccord Genuity released a primer into five psychedelic companies that they “believe could mature into leaders within their
Read more
Psyched Wellness Completes Maximum Tolerated Dosage Study For Amanita Muscaria Extract AME-1
Psyched Wellness (CSE: PSYC) this morning issued a brief press release related to the ongoing pre-clinical trial of its muscimol
Read more